Medical Condition News

RSS

Genetic risk factor for schizophrenia can disrupt connectivity at level of single neurons

The strongest known recurrent genetic cause of schizophrenia impairs communications between the brain's decision-making and memory hubs, resulting in working memory deficits, according to a study in mice.

1 Apr 2010

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.

1 Apr 2010

Advocates urge Representatives to support Colorectal Cancer Prevention, Early Detection and Treatment Act

On March 30-31, 2010, advocates from all 50 states, the District of Columbia and Puerto Rico called their Representatives in Congress, urging them to support the Colorectal Cancer Prevention, Early Detection and Treatment Act (H.R. 1189) during the annual Congressional Butt-In.

1 Apr 2010

Series of awareness and fundraising initiatives to take place throughout Autism Awareness Month

Autism Speaks Canada, today announced a series of awareness and fundraising initiatives involving a range of corporate and philanthropic partners that will take place throughout Autism Awareness Month in April.

1 Apr 2010

Scientists use non-viral, synthetic nanoparticle carrier to restores vision

Take a look at this: Scientists from Buffalo, Cleveland, and Oklahoma City made a huge step toward making the blind see, and they did it by using a form of gene therapy that does not involve the use of modified viruses.

1 Apr 2010

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

Using new one-of-a-kind "mouse models" that promise to have a significant impact on future Parkinson's disease research, Mount Sinai School of Medicine researchers are among the first to discover how mutations in a gene called LRRK2 may cause inherited (or "familial") Parkinson's disease, the most common form of the disease. The study, published in The Journal of Neuroscience, is the first in vivo evidence that LRRK2 regulates dopamine transmission and controls motor performance, and that the mutation of LRRK2 eliminates the normal function of LRRK2, leading to Parkinson's disease.

1 Apr 2010

New book from AGA helps patients self-manage their IBD and challenges

Inflammatory bowel disease strikes young people between the ages of 15 and 30 most often, but it can appear at any age. It is easy to for the 100,000 people diagnosed with IBD - Crohn's disease and ulcerative colitis - each year to feel powerless against this condition, but now, a new book from the AGA helps patients self-manage their IBD and the challenges they face.

1 Apr 2010

Red Hill Studios, UCSF awarded two grants to develop computer-based physical therapy games

Red Hill Studios, a California-based serious games developer, in partnership with the UCSF School of Nursing, has been awarded two grants totaling $1.1 million from the National Institutes of Health to continue development, production and testing of computer-based physical therapy games for patients with Parkinson's disease and cerebral palsy.

1 Apr 2010

Combating immune suppressive cells in liver may prevent the spread of cancer: Study

Scientists have uncovered what could be a very important clue in answering one of the most perplexing questions about cancer: why does it spread to the liver more than any other organ? In a new research report published in the April 2010 issue of Journal of Leukocyte Biology, scientists from New York University describe experimental results suggesting that the immune system may be the reason.

1 Apr 2010

Metabolon awarded U.S. patents for metabolomics methods

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.

1 Apr 2010

Researchers develop experimental protocol to detect age-related memory disorders

By studying the aging of memory in the mouse, researchers in the Laboratoire Neurobiologie des Processus Adaptatifs have developed an experimental protocol that can detect age-related memory deficits at an early stage. They have shown that even at 10 months, which corresponds to a third of their life expectancy, some mice present with age-related memory disorders.

1 Apr 2010

Conventional analgesics to drive acute pain market over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, the launches and uptake of reformulations of conventional analgesics will drive annual three percent growth in the acute pain drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

1 Apr 2010

Neurologist develops SAGE tool to diagnose memory disorders

A self-administered test to screen for early dementia could help speed the diagnosis and subsequent treatment of memory disorders, including Alzheimer's disease. It could also provide health care providers and caregivers an earlier indication of life-changing events that could lie ahead.

1 Apr 2010

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

Role of membrane cholesterol in late keratinocyte differentiation analyzed

In a recent study initiated by Beiersdorf AG, Florian Spörl and colleagues evaluated the use of Roche Applied Science's xCELLigence System as a viable system to monitor not only cholesterol extraction and repletion but also cholesterol reorganization in human keratinocytes in real time. The xCELLigence System offers a novel approach to non-invasive long-term observation of membrane cholesterol dynamics in primary human keratinocytes.

1 Apr 2010

PanGenex releases statement on Omega-3 and Lipideme

PanGenex Corporation a global manufacturer and distributor of nutraceutical and dietary supplement products, today released a statement in response to the many inquiries about Omega-3 and Lipideme.

1 Apr 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

TCA may be an effective treatment option for patients who suffer from PVOD

Traditional Chinese acupuncture, where very thin needles are used to stimulate specific points in the body to elicit beneficial therapeutic responses, may be an effective treatment option for patients who suffer from persistent post- viral olfactory dysfunction, according to new research in the April 2010 issue of Otolaryngology - Head and Neck Surgery.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Rudd proposes that GP’s take on care of diabetics

In a bid to ease the strain caused by diabetes on the hospitals, Australian Prime Minister, Kevin Rudd has proposed that GP’s take on care of diabetics. For every diabetes patient that a GP handles, the government will pay the doctor $1200 a year to cover day-to-day costs. Each GP will receive up to $10,800 annually based on performance.

1 Apr 2010

Medical Condition News

Genetic risk factor for schizophrenia can disrupt connectivity at level of single neurons

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Advocates urge Representatives to support Colorectal Cancer Prevention, Early Detection and Treatment Act

Series of awareness and fundraising initiatives to take place throughout Autism Awareness Month

Scientists use non-viral, synthetic nanoparticle carrier to restores vision

Insight into how mutations in LRRK2 gene may cause familial Parkinson's disease

New book from AGA helps patients self-manage their IBD and challenges

Red Hill Studios, UCSF awarded two grants to develop computer-based physical therapy games

Combating immune suppressive cells in liver may prevent the spread of cancer: Study

Metabolon awarded U.S. patents for metabolomics methods

Researchers develop experimental protocol to detect age-related memory disorders

Conventional analgesics to drive acute pain market over the next decade

Neurologist develops SAGE tool to diagnose memory disorders

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Role of membrane cholesterol in late keratinocyte differentiation analyzed

PanGenex releases statement on Omega-3 and Lipideme

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

TCA may be an effective treatment option for patients who suffer from PVOD

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Rudd proposes that GP’s take on care of diabetics

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News